Univariate relationships between EM and clinical outcomes
| . | GVH . | HVG . | ||||
|---|---|---|---|---|---|---|
| Outcome . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Class I EM | ||||||
| Relapse | 1.011 | 0.965-1.059 | NS | 1.015 | 0.975-1.058 | NS |
| OS | 1.014 | 0.976-1.053 | NS | 1.034 | 0.996-1.074 | .082 |
| RFS | 1.019 | 0.984-1.056 | NS | 1.035 | 1.000-1.072 | .049 |
| TRM | 1.012 | 0.962-1.064 | NS | 1.032 | 0.978-1.088 | NS |
| aGVHD | 0.991 | 0.954-1.030 | NS | — | — | — |
| cGVHD | 0.981 | 0.933-1.033 | NS | — | — | — |
| Neutrophil engraftment | — | — | — | 0.975 | 0.949-1.003 | .075 |
| Platelet engraftment | — | — | — | 0.974 | 0.945-1.003 | .079 |
| Class II EM | ||||||
| Relapse | 0.966 | 0.938-0.995 | .023 | 0.994 | 0.964-1.025 | NS |
| OS | 0.983 | 0.961-1.006 | .145 | 1.009 | 0.985-1.033 | NS |
| RFS | 0.978 | 0.957-0.999 | .037 | 1.007 | 0.985-1.029 | NS |
| TRM | 1.006 | 0.976-1.037 | NS | 1.013 | 0.982-1.046 | NS |
| aGVHD | 1.004 | 0.978-1.030 | NS | — | — | — |
| cGVHD | 1.007 | 0.977-1.039 | NS | — | — | — |
| Neutrophil engraftment | — | — | — | 0.976 | 0.955-0.997 | .027 |
| Platelet engraftment | — | — | — | 0.971 | 0.950-0.993 | .010 |
| Total EM | ||||||
| Relapse | 0.978 | 0.954-1.004 | .091 | 1.000 | 0.978-1.023 | NS |
| OS | 0.991 | 0.972-1.011 | NS | 1.015 | 0.995-1.035 | .142 |
| RFS | 0.989 | 0.971-1.007 | NS | 1.014 | 0.996-1.032 | .137 |
| TRM | 1.008 | 0.983-1.033 | NS | 1.018 | 0.989-1.048 | NS |
| aGVHD | 1.000 | 0.979-1.023 | NS | — | — | — |
| cGVHD | 1.000 | 0.973-1.028 | NS | — | — | — |
| Neutrophil engraftment | — | — | — | 0.977 | 0.959-0.996 | .015 |
| Platelet engraftment | — | — | — | 0.975 | 0.958-0.992 | .004 |
| . | GVH . | HVG . | ||||
|---|---|---|---|---|---|---|
| Outcome . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Class I EM | ||||||
| Relapse | 1.011 | 0.965-1.059 | NS | 1.015 | 0.975-1.058 | NS |
| OS | 1.014 | 0.976-1.053 | NS | 1.034 | 0.996-1.074 | .082 |
| RFS | 1.019 | 0.984-1.056 | NS | 1.035 | 1.000-1.072 | .049 |
| TRM | 1.012 | 0.962-1.064 | NS | 1.032 | 0.978-1.088 | NS |
| aGVHD | 0.991 | 0.954-1.030 | NS | — | — | — |
| cGVHD | 0.981 | 0.933-1.033 | NS | — | — | — |
| Neutrophil engraftment | — | — | — | 0.975 | 0.949-1.003 | .075 |
| Platelet engraftment | — | — | — | 0.974 | 0.945-1.003 | .079 |
| Class II EM | ||||||
| Relapse | 0.966 | 0.938-0.995 | .023 | 0.994 | 0.964-1.025 | NS |
| OS | 0.983 | 0.961-1.006 | .145 | 1.009 | 0.985-1.033 | NS |
| RFS | 0.978 | 0.957-0.999 | .037 | 1.007 | 0.985-1.029 | NS |
| TRM | 1.006 | 0.976-1.037 | NS | 1.013 | 0.982-1.046 | NS |
| aGVHD | 1.004 | 0.978-1.030 | NS | — | — | — |
| cGVHD | 1.007 | 0.977-1.039 | NS | — | — | — |
| Neutrophil engraftment | — | — | — | 0.976 | 0.955-0.997 | .027 |
| Platelet engraftment | — | — | — | 0.971 | 0.950-0.993 | .010 |
| Total EM | ||||||
| Relapse | 0.978 | 0.954-1.004 | .091 | 1.000 | 0.978-1.023 | NS |
| OS | 0.991 | 0.972-1.011 | NS | 1.015 | 0.995-1.035 | .142 |
| RFS | 0.989 | 0.971-1.007 | NS | 1.014 | 0.996-1.032 | .137 |
| TRM | 1.008 | 0.983-1.033 | NS | 1.018 | 0.989-1.048 | NS |
| aGVHD | 1.000 | 0.979-1.023 | NS | — | — | — |
| cGVHD | 1.000 | 0.973-1.028 | NS | — | — | — |
| Neutrophil engraftment | — | — | — | 0.977 | 0.959-0.996 | .015 |
| Platelet engraftment | — | — | — | 0.975 | 0.958-0.992 | .004 |
GVH (median, 24; range, 0-51); HVG (median, 25; range, 0-47).
—, test not performed.